2025

​

Siriwong, N., Sriphoosanaphan, S., Decharatanachart, P., Yongpisarn, T., Kerr, S. J., Treeprasertsuk, S., Tiyarattanachai, T., Apiparakoon, T., Hagstrom, H., Akbari, C., Ekstedt, M., Yip, T. C., Wong, G. L., Ito, T., Ishigami, M., Toyoda, H., Peleg, N., Shlomai, A., Seko, Y., Sumida, Y., Kawanaka, M., Hino, K., and Chaiteerakij, R.

 Role of noninvasive tests on the prediction of hepatocellular carcinoma in nonalcoholic fatty liver disease patients without cirrhosis: a systematic review and meta-analysis of aggregate and individual patient data

​

 Eur J Gastroenterol Hepatol 37, 358-369

​

Shafran, N., Atamna, A., Inbar, E., Soudry, E., Sternov, Y., Saleh, L., Zvi, H. B., Shlomai, A., and Bishara, J.

 Fatal invasive Apophysomyces variabilis infection in a frequent traveler to Mecca, Saudi Arabia 

​

Journal of Travel Medicine  10.1093/jtm/taaf012taaf012

​

2024

​

Yu, Y., Kass, M. A., Zhang, M., Youssef, N., Freije, C. A., Brock, K. P., Aguado, L. C., Seifert, L. L., Venkittu, S., Hong, X., Shlomai, A., de Jong, Y. P., Marks, D. S., Rice, C. M., and Schneider, W. M.  Deep mutational scanning of hepatitis B virus reveals a mechanism for cis-preferential reverse transcription

 

Cell 187, 2735-2745 e2712

​

Goldstein, A., Neuberger, A., Darawsha, Y. Q., Hussein, K., Shafat, T., Grupel, D., Strahilevitz, J., Israel, S., Weil, A., Ben-Ami, R., Elbaz, M., Najjar-Debbiny, R., Bishara, J., Shlomai, A*., and Landes, M.* (*Equal contribution)

 Clinical outcomes of immunomodulation therapy in immunocompromised patients with severe Covid-19 and high oxygen requirement

 

Sci Rep 14, 16985

 

2023

​Yu, Y., Schneider, W. M., Kass, M. A., Michailidis, E., Acevedo, A., Pamplona Mosimann, A. L., Bordignon, J., Koenig, A., Livingston, C. M., van Gijzel, H., Ni, Y., Ambrose, P. M., Freije, C. A., Zhang, M., Zou, C., Kabbani, M., Quirk, C., Jahan, C., Wu, X., Urban, S., You, S., Shlomai, A., de Jong, Y. P., and Rice, C. M.

 An RNA-based system to study hepatitis B virus replication and evaluate antivirals

 

Sci Adv 2023 Apr 14;9(15):eadg6265.

​

Shostak, Y., Kramer, M. R., Edni, O., Glusman Bendersky, A., Shafran, N., Bakal, I., Heching, M., Rosengarten, D., Shitenberg, D., Amor, S. M., Ben Zvi, H., Pertzov, B., Cohen, H., Rotem, S., Elia, U., Chitlaru, T., Erez, N., Peysakhovich, Y., Y, D. B., Shlomai, A., Bar-Haim, E., and Shtraichman, O.

 Immunogenicity of a Third Dose of BNT162b2 Vaccine among Lung Transplant Recipients-A Prospective Cohort Study

​

Vaccines (Basel) 2023 Apr 4;11(4):799,

 

Ofri, I., Peleg, N., Leshno, M., and Shlomai, A.

 A decision-making model for prediction of a stable disease course in chronic hepatitis B patients 

​

Sci Rep 13, 23051

​

Mao, X., Cheung, K. S., Peng, C., Mak, L. Y., Cheng, H. M., Fung, J., Peleg, N., Leung, H. H., Kumar, R., Lee, J. H., Shlomai, A., Yuen, M. F., and Seto, W. K.

Steatosis, HBV-related HCC, cirrhosis, and HBsAg seroclearance: A systematic review and meta-analysis 

​

Hepatology 77, 1735-1745

​

2022

​

Sofer, S., Lamkiewicz, K., Armoza Eilat, S., Partouche, S., Marz, M., Moskovits, N., Stemmer, S. M., Shlomai, A., and Sklan, E. H.

A genome-wide CRISPR activation screen reveals Hexokinase 1 as a critical factor in promoting resistance to multi-kinase inhibitors in hepatocellular carcinoma cells

 

FASEB J 2022 Mar;36(3):e22191

​

Siman-Tov, R., Shalabi, R., Shlomai, A., Goldberg, E., Essa, W., Shusterman, E., Ablin, J. N., Caspi, M., Rosin-Arbesfeld, R., and Sklan, E. H.

 Elevated Serum Amyloid A Levels Contribute to Increased Platelet Adhesion in COVID-19 Patients

 

Int J Mol Sci 2022 Nov 17;23(22):14243.

 

Goyal, A., Churkin, A., Barash, D., Cotler, S. J., Shlomai, A., Etzion, O., and Dahari, H.

Modeling-Based Response-Guided DAA Therapy for Chronic Hepatitis C to Identify Individuals for Shortening Treatment Duration

 

Open Forum Infect Dis 2022 Mar 22;9(5):ofac157

​

Churkin, A., Kriss, S., Uziel, A., Goyal, A., Zakh, R., Cotler, S. J., Etzion, O., Shlomai, A., Rotstein, H. G., Dahari, H., and Barash, D.

 Machine learning for mathematical models of HCV kinetics during antiviral therapy 

​

Math Biosci 2022 Jan:343:108756.

2021

N. Shafran, I. Shafran, H. Ben-Zvi, S. Sofer, L. Sheena, I. Krause, A. Shlomai *, E. Goldberg* and E. H. Sklan* (* equal contribution).

Secondary bacterial infection in COVID-19 patients is a stronger predictor for death compared to influenza patients.

​

Scientific Reports 2021 11(1): 12703.

​

Shafran N, Issachar A, Shochat T, Shafran IH, Bursztyn M, Shlomai A.       
Abnormal liver tests in patients with SARS-CoV-2 or influenza-prognostic similarities and temporal disparities.

​

JHEP Reports. 2021Jun;3(3):100258.

 

Goldberg, E.*, H. Ben Zvi*, L. Sheena, S. Sofer, I. Krause, E. H. Sklan* and A. Shlomai*
(* equal contribution).

A real-life setting evaluation of the effect of remdesivir on viral load in COVID-19 patients admitted to a large tertiary center in Israel.

​

Clinical Microbiology and Infection 2021 Jun; 27(6): 917.e1–917.e4

​

Dahari, H., Shlomai, A., and Cotler, S. J.
Early HBV RNA kinetics under NA treatment may reveal new insights into HBV RNA dynamics and NA mode of action-more detailed kinetic studies are needed.

​

Journal of Viral Hepatitis 2021 Apr;28(4):687-688

​

2020

Shlomai, A., Leshno, A., Sklan, E. H., and Leshno, M.

Modeling Social Distancing Strategies to Prevent SARS-CoV-2 Spread in Israel: A Cost-Effectiveness Analysis.

​

Value in Health 2021 May;24(5):607-614

​

Kolodziejczyk, A. A., S. Federici, N. Zmora, G. Mohapatra, M. Dori-Bachash, S.

Hornstein, A. Leshem, D. Reuveni, E. Zigmond, A. Tobar, T. M. Salame, A. Harmelin, A. Shlomai, H. Shapiro, I. Amit and E. Elinav.

Acute liver failure is regulated by MYC- and microbiome-dependent programs.

Nature Medicine 2020 Dec;26(12):1899-1911

​

Etzion, O., H. Dahari, D. Yardeni, A. Issachar, A. Nevo-Shor, M. Cohen-Naftaly, Y. Ashur, S. L. Uprichard, O. S. Arbib, D. Munteanu, M. Braun, S. J. Cotler, N. Abufreha, A. Keren-Naus, Y. Shemer-Avni, O. Mor, J. Murad, V. Novack and A. Shlomai.

Response guided therapy for reducing duration of direct acting antivirals in chronic hepatitis C infected patients: a Pilot study.

​

Scientific Reports 2020; 10: 17820.

​

Shlomai, A., H. Ben-Zvi, A. Glusman Bendersky, N. Shafran, E. Goldberg and E. H. Sklan.

Nasopharyngeal viral load predicts hypoxemia and disease outcome in admitted COVID-19 patients.

​

Critical care 2020; 24(1): 539-539.

​

Taylor, R. S., R. J. Taylor, S. Bayliss, H. Hagstrom, P. Nasr, J. M. Schattenberg, M. Ishigami, H. Toyoda, V. Wai-Sun Wong, N. Peleg, A. Shlomai, G. Sebastiani, Y. Seko, N. Bhala, Z. M. Younossi, Q. M. Anstee, S. McPherson and P. N. Newsome.

Association Between Fibrosis Stage and Outcomes of Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis.

​

Gastroenterology 2020 Feb 4:S0016-5085(20)30137-2.

​

Deutsch L, Houri I, Ben-Ari Z, Shlomai A, Veitsman E, Cohen-Ezra O, Issachar A, Mor O, Gozlan Y, Bruck R, Menachem Y, Zelber-Sagi S, Katchman H, Shibolet O.

Ombitasvir/paritaprevir/ritonavir & dasabuvir ± ribavirin following protease inhibitors failure - a prospective multi-center trial.

​

BMC Infect Dis 2020 Apr 3;20(1):264.

​

Michailidis, E., K. Vercauteren, L. Mancio-Silva, L. Andrus, C. Jahan, I. Ricardo-Lax, C. Zou, M. Kabbani, P. Park, C. Quirk, C. Pyrgaki, B. Razooky, L. Verhoye, I. Zoluthkin, W. Y. Lu, S. J. Forbes, L. Chiriboga, N. D. Theise, R. W. Herzog, H. Suemizu, W. M. Schneider, A. Shlomai, P. Meuleman, S. N. Bhatia, C. M. Rice and Y. P. de Jong.

Expansion, in vivo-ex vivo cycling, and genetic manipulation of primary human hepatocytes.

​

Proc Natl Acad Sci U S A 2020 117(3): 1678-1688.

​

Berger T, Reisler I, Shochat T, Raanani P, Mor E, Gafter-Gvili A, Shlomai A.

Post liver transplantation anemia and its correlation with mortality and graft Failure.

​

Digestive Diseases and Sciences 2020 Oct;65(10):3040-3051.

  

​

 2019

Shlomai A, Leshno M and Goldstein DA.

 Cabozantinib for patients with advanced hepatocellular carcinoma – a cost-effectiveness analysis

Therapeutic Advances in Gastroenterology 2019. Sep 23;12:1756284819878304.

​

Peleg N, Issachar A, Sneh-Arbib O, Cohen-Naftaly M, Harif Y, Oxtrud E, Braun M, Leshno M,  Barsheshet A, Shlomai A.

 Liver steatosis is a major predictor of poor outcomes in chronic hepatitis C patients with sustained virologic response

J Viral Hepatitis 2019 26(11):1257-1265.

​

Shirin D., Peleg N., Sneh-Arbib O., Cohen-Naftaly M., Braun M., Shochat T., Issachar A., and Shlomai A.

The Pattern of Elevated Liver Function Tests in Nonalcoholic Fatty Liver Disease Predicts Fibrosis Stage and Metabolic-Associated Comorbidities.      

Digestive Diseases 2019;37(1):69-76

​

Peleg N, Issachar A, Sneh Arbib O, Cohen-Naftaly M, Braun M, Leshno M, Barsheshet A, Shlomai A.

 Liver steatosis is a strong predictor of mortality and cancer in chronic hepatitis B regardless of viral load

JHEP Reports. 2019 1 pp. 8-14

​

Gozlan Y., Bucris E., Shirazi R., Rakovsky A., Ben-Ari Z., Davidov Y., Veizman E., Saadi T., Braun M., Cohen-Naftaly M., Shlomai A., Shibolet O., Zigmond E., Katchman H., Menachem Y., Safadi R., Galun E., Zuckerman E., Nimer A., Hazzan R., Maor Y., Saif A. M., Etzion O., Lurie Y., Mendelson E., and Mor O.

High frequency of multiclass HCV resistance-associated mutations in patients failing direct-acting antivirals: real-life data.

Antiviral therapy. 2019 24(3):221-228
 

2018

Wiessman, M and Shlomai A. (Letter to the Editor)
Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection.

The New England Journal of Medicine 2018;378(26) 2539

​

Nesher E., Braun M., Eizner S., Issachar A., Cohen M., Shlomai A., Gurevich M., Tur-Kaspa R., and Mor E.

Transplantation of Livers from Old Donors: Pushing the Envelope Beyond the Seventh Decade.

 Isr Med Assoc J. 2018 20, 765-769

​

Shlomai A., Leshno M., and Goldstein D. A.

Regorafenib treatment for patients with hepatocellular carcinoma who progressed on sorafenib—A cost-effectiveness analysis.

PLOS ONE 2018 13 (11), e0207132  

​

Van Dijk T. Y., Rahamimov R., Chagnac A., van Dijk D. J., Mor E., Shlomai A., and Rozen-Zvi B.

 The Effect of Cause, Timing, Kidney Function Recovery and Recurrent Events on the Prognosis of Acute Kidney Injury in Kidney Transplant Recipients.

Clinical Transplantation, 2018 Oct;32(10):e13398   

​

Peleg N., Sneh Arbib O., Issachar A., Cohen-Naftaly M., Braun M., and Shlomai A.
Noninvasive scoring systems predict hepatic and extra-hepatic cancers in patients with nonalcoholic fatty liver disease.

PLOS ONE 2018 13(8), e0202393

​

Dukhovny A., Shlomai A., and Sklan E. H.

The antiviral protein Viperin suppresses T7 promoter dependent RNA synthesis–possible implications for its antiviral activity.

Scientific reports 2018; 8, 8100

​

Witt-Kehati D, Fridkin A, Alaluf MB, Zemel R, Shlomai A.

Inhibition of pMAPK14 Overcomes Resistance to Sorafenib in Hepatoma Cells with Hepatitis B Virus.

Transl Oncol. 2018;11(2):511-517.

​

Shirazi R, Ram D, Rakovsky A, Bucris E, Gozlan Y, Lustig Y, Shaked-Mishan P, Picard O, Shemer-Avni Y, Ben-Zvi H, Halutz O, Lurie Y, Veizman E, Carlebach M, Braun M, Naftaly MC, Shlomai A, Safadi R, Mendelson E, Sklan EH, Ben-Ari Z, Mor O.

Characterization of hepatitis B and delta coinfection in Israel.

BMC Infect Dis. 2018;18(1):97.
 

2017

Gozlan Y, Ben-Ari Z, Moscona R, Shirazi R, Rakovsky A, Kabat A, Veizman E, Berdichevski T, Weiss P, Cohen-Ezra O, Lurie Y, Gafanovich I, Braun M, Cohen-Naftaly M, Shlomai A, Shibolet O, Zigmond E, Zuckerman E, Carmiel-Haggai M, Nimer A, Hazzan R, Maor Y, Kitay-Cohen Y, Shemer Y, Kra-Oz Z, Schreiber L, Peleg O, Mendelson E, Mor O.

 HCV genotype-1 subtypes and resistance-associated substitutions in drug-naive and in direct-acting antiviral treatment failure patients.

Antivir Ther. 2017; 22(5):431-441

 

Leibovici-Weissman Y, Mor E, Leshno M*, Shlomai A*.

(*Equal contribution)

Patients' Age Rather Than Model of End-Stage Liver Disease Score Predicts Survival After Liver Transplantation.

Dig Dis Sci. 2017;62(3):801-807.

 

Nesher E, Mor E, Shlomai A, Naftaly-Cohen M, Yemini R, Yussim A, Brown M, Keidar A.

Simultaneous Liver Transplantation and Sleeve Gastrectomy: Prohibitive Combination or a Necessity?

Obes Surg 2017;27(5):1387-1390

 

Peleg N, Issachar A, Sneh-Arbib O, Shlomai A.

AST to Platelet Ratio Index and fibrosis 4 calculator scores for non-invasive assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease.

Dig Liver Dis. 2017; 49(10):1133-1138.

 

Michailidis E, Pabon J, Xiang K, Park P, Ramanan V, Hoffmann H-H, Schneider WM, Bhatia SN, de Jong YP, Shlomai A, Rice CM.

A robust cell culture system supporting the complete life cycle of hepatitis B virus.

Scientific reports 2017;7(1):16616.

​

2016

Scheel Troels KH, Luna Joseph M, Liniger M, Nishiuchi E, Rozen-Gagnon K, Shlomai A, Auray G, Gerber M, Fak J, Keller I, Bruggmann R, Darnell RB, Ruggli N, Rice CM.

A Broad RNA Virus Survey Reveals Both miRNA Dependence and Functional Sequestration.

Cell Host Microbe 2016;19(3):409-23.

 

Billerbeck E, Mommersteeg MC, Shlomai A, Xiao JW, Andrus L, Bhatta A, Vercauteren K, Michailidis E, Dorner M, Krishnan A, Charlton MR, Chiriboga L, Rice CM, de Jong YP.

Humanized mice efficiently engrafted with fetal hepatoblasts and syngeneic immune cells develop human monocytes and NK cells.

J Hepatol. 2016;65(2):334-43.

 

Witt-Kehati D, Bitton Alaluf M, Shlomai A.

Advances and Challenges in Studying Hepatitis B Virus In Vitro.

Viruses 2016;8:21.

 

Bitton Alaluf M and Shlomai A.

New therapies for chronic hepatitis B.
Liver International 2016;36(6):775-782.

​

Hasin Y, Shteingart S, Dahari H, Gafanovich I, Floru S, Braun M,Shlomai A , Verstandig A, Dery I, Uprichard SL, Cotler SJ, Lurie Y.

Hepatitis C virus cures after direct acting antiviral-related drug-induced liver injury: Case report. 

World J Hepatol ; 2016; 8(20): 858-862

​

2015

Shlomai A, Tobar A, Benjaminov O. 2015.
Multiple liver lesions after oxaliplatin-based chemotherapy for colorectal cancer.

Gastroenterology 2015;149(6):e1-3.

 

Shlomai A.
Hepatitis C virus addiction to liver miR-122 takes its toll on the host.

Hepatology 2015;62(5):1633-5

​

Ramanan V*, Shlomai A*, Cox DBT*, Schwartz RE, Michailidis E, Bhatta A, Scott DA, Zhang F, Rice CM, Bhatia SN.

 (*equal contribution)

CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus.

Sci Rep. 2015 Jun 2;5:10833

    

Ricardo-Lax I, Ramanan V, Michailidis E, Shamia T, Reuven N, Rice CM, Shlomai A*,Shaul Y*.

 Hepatitis B virus induces RNR-R2 expression via DNA damage response activation.
(*corresponding authors)

 J Hepatol. 2015 Oct;63(4):789-96.

 

March S, Ramanan V, Trehan K, Ng S, Galstian A, Gural N, Scull MA, Shlomai A, Mota MM, Fleming HE, Khetani SR, Rice CM, Bhatia SN.

Micropatterned coculture of primary human hepatocytes and supportive cells for the study of hepatotropic pathogens.

Nat Protoc. 2015;10(12):2027-53.

​

2014

Shlomai, A., de Jong, Y.P., and Rice, C.M.

Virus associated malignancies: The role of viral hepatitis in hepatocellular carcinoma.

Seminars in Cancer Biology.2014;26:78-88

​

Shlomai A*, Schwartz RE*, Ramanan V*, Bhatta A, de Jong YP, Bhatia SN, Rice CM.

Modeling host interactions with hepatitis B virus using primary and induced pluripotent stem cell-derived hepatocellular systems.

Proc Nat Acad Sci. 2014;111:12193-12198. (*equal contribution)

​

Shlomai, A., and Rice, C.M.

Getting Rid of a Persistent Troublemaker to Cure Hepatitis.

Science 2014;343:1212-1213.

​

2013

Ben-Shlomo S, Zvibel I, Rabinowich L, Goldiner I, Shlomai A, Santo EM, Halpern Z, Oren R, Fishman S.

Dipeptidyl Peptidase 4-Deficient Rats Have Improved Bile Secretory Function in High Fat Diet-Induced Steatosis.

Dig Dis Sci. 2013;58(1):172-8.

 

Ben-Shlomo S, Zvibel I, Varol C, Spektor L, Shlomai A, Santo EM, Halpern Z, Oren R, Fishman S.

 Role of Glucose-Dependent Insulinotropic Polypeptide in Adipose Tissue Inflammation of Dipeptidylpeptidase 4-Deficient Rats.

Obesity (Silver Spring). 2013;21:2331-41.

 

Mouler Rechtman M, Burdelova EO, Bar-Yishay I, Ben-Yehoyada M,

 Fishman S, Halpern Z, Shlomai A.

 The metabolic regulator PGC-1alpha links anti-cancer cytotoxic chemotherapy to reactivation of hepatitis B virus.

J Viral Hepat. 2013;20:34-41.

 

Shlomai A,Halfon P, Goldiner I, Zelber-Sagi S, Halpern Z, Oren R, Bruck R.

 Serum bile acid levels as a predictor for the severity of liver fibrosis in patients with chronic hepatitis C.

J Viral Hepat. 2013;20:95-102.

 

Adamovich Y, Shlomai A,Tsvetkov P, Umansky KB, Reuven N, Estall JL, Spiegelman BM, Shaul Y.

The Protein Level of PGC-1 alpha, a Key Metabolic Regulator, Is Controlled by NADH-NQO1.

Mol Cell Biol. 2013;33:2603-13.

​

2012

Sikuler, E., Ackerman, Z., Braun, M., Baruch, Y., Bruck, R., Safadi, R.,Shlomai A . and Ben-Ari, Z.

[Guidelines for diagnosis and management of cirrhotic ascites and its complications.

The Israeli Association for the Study of the Liver].

Harefua 2012.151:705-708, 719.
 

Ben-Shlomo S, Einstein FH, Zvibel I, Atias D, Shlomai A, Halpern Z,

Barzilai N, Fishman S.

Perinephric and epididymal fat affect hepatic metabolism in rats.

Obesity (Silver Spring). 2012;20:151-6.

 

Shlomai A, Rechtman MM, Burdelova EO, Zilberberg A, Hoffman S, Solar I, Fishman S, Halpern Z, Sklan EH.

The metabolic regulator PGC-1alpha links hepatitis C virus infection to hepatic insulin resistance.

J Hepatol. 2012;57:867-73.

 

Zelber-Sagi S, Lotan R, Shlomai A, Webb M, Harrari G, Buch A,

Nitzan Kaluski D, Halpern Z, Oren R.

 Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up.

J Hepatol. 2012;56:1145-51.

​

2011

Shlomai, A.

Targeting late SV40 factor: Is the achilles heel of hepatocarcinogenesis revealed?

World J Gastroenterol 2011;18:6709-6711.

 

Ben-Shlomo S, Zvibel I, Shnell M, Shlomai A, Chepurko E, Halpern Z,

Barzilai N, Oren R, Fishman S.

Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase.

J Hepatol. 2011;54:1214-23.

 

Tchebiner JZ, Nutman A, Boursi B, Shlomai A, Sella T, Wasserman A. Guzner-Gur H.

Diagnostic and prognostic value of thrombocytosis in admitted medical patients.

Am J Med Sci. 2011;342:395-401.

 

Zelber-Sagi S, Yeshua H, Shlomai A, Blendis L, Leshno M, Levit S,

Halpern Z, Oren R.

Sampling variability of transient elastography according to probe location.

Eur J Gastroenterol Hepatol. 2011;23:507-14.

​

Bar-Yishay, I., Shaul, Y., and Shlomai A.

Hepatocyte metabolic signalling pathways and regulation of hepatitis B virus expression.

Liver Int 2011;31:282-290.

​

2010

Rechtman MM, Har-Noy O, Bar-Yishay I, Fishman S, Adamovich Y, Shaul Y, Halpern Z, Shlomai A.

Curcumin inhibits hepatitis B virus via down-regulation of the metabolic coactivator PGC-1alpha.

FEBS Lett. 2010;584:2485-90.

​

Shlomai A*, Kariv R*, Leshno M, Beth-Or A, Sheinberg B, Halpern Z.

Large-scale population analysis reveals an extremely low threshold for "non-healthy" alanine aminotransferase that predicts diabetes mellitus.

J Gastroenterol Hepatol. 2010;25:1687-91. (*equal contribution)

 

Shlomai A, Nutman A, Kotlovsky T, Schechner V, Carmeli Y, Guzner-Gur H.

Predictors of pandemic (H1N1) 2009 virus positivity and adverse outcomes among hospitalized patients with a compatible syndrome.

Isr Med Assoc J. 2010;12:622-7.

​

Shlomai, A., and Guzner-Gur, H.

Ectopic splenomegaly.

Intern Med J 2010;40:600.

​

Before 2009

Shlomai A, Shaul Y.

The metabolic activator FOXO1 binds hepatitis B virus DNA and activates its transcription. Biochem Biophys Res Commun. 2009;381:544-8.

​

Shlomai A, Lubelsky Y, Har-Noy O, Shaul Y.

The "Trojan horse" model-delivery of anti-HBV small interfering RNAs by a recombinant HBV vector.

Biochem Biophys Res Commun. 2009;390:619-23.

​

Shlomai A, Shaul Y.

The "metabolovirus" model of hepatitis B virus suggests nutritional therapy as an effective anti-viral weapon.

Med Hypotheses. 2008;71:53-7.

​

Shlomai A, Paran N, Shaul Y.

PGC-1alpha controls hepatitis B virus through nutritional signals.

Proc Natl Acad Sci U S A. 2006;103:16003-8.

​

Shlomai, A., Hershko, A.Y., Gabbay, E., and Ben-Chetrit, E.

Clinical and radiographic features mimicking pulmonary embolism as the first manifestation of Takayasu's arteritis.

Clin Rheumatol 2004;23:470-472.

​

Shlomai, A., and Shaul, Y.

RNA interference--small RNAs effectively fight viral hepatitis.

Liver Int 2004;24:526-531.

​

Shlomai A, Shaul Y.

Inhibition of hepatitis B virus expression and replication by RNA interference.

Hepatology. 2003;37:764-70.

​

Shlomai A, Trop S, Gotsman I, Jurim O, Diment J, Alper R, Rabbani E, Engelhardt D, Ilan Y.

Immunomodulation of experimental colitis: the role of NK1.1 liver lymphocytes and surrogate antigens--bystander effect.

J Pathol. 2001;195:498-507.

​

Gotsman I, Shlomai A, Alper R, Rabbani E, Engelhardt D, Ilan Y.

Amelioration of immune-mediated experimental colitis: tolerance induction in the presence of preexisting immunity and surrogate antigen bystander effect.

J Pharmacol Exp Ther. 2001;297:926-32.

​
 

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

 

​